Hormonal
In postmenopausal breast cancer survivors, higher adiposity (BMI, body fat mass, waist circumference) is significantly associated with higher circulating levels of estrone, estradiol, testosterone, and free testosterone, and lower levels of sex hormone-binding globulin (SHBG).
For postmenopausal breast cancer survivors, maintaining a healthy body weight is crucial because excess body fat directly increases levels of estrogen and testosterone, which can fuel cancer growth. While you cannot change your genetics, managing body fat through diet and physical activity may help lower these hormone levels, potentially improving your prognosis. Focus on overall fat reduction rather than just waist size, as total body fat mass is the key driver.
Obese women (BMI > 30) had 35% higher concentrations of estrone and 130% higher concentrations of estradiol compared with lighter-weight women (BMI < 22.0; P < .005 and .002, respectively). Similar associations were observed for body fat mass, percent body fat, and waist circumference. Testosterone concentrations also increased with increasing levels of adiposity (P < .0001). Concentrations of free estradiol and free testosterone were two to three times greater in overweight and obese women compared with lighter-weight women (P < .0001).
Why this rating
Large population-based cohort (n=505 postmenopausal women), rigorous statistical adjustment for confounders, but cross-sectional design limits causal inference.
Source
Adiposity and Sex Hormones in Postmenopausal Breast Cancer Survivors
Anne McTiernan et al. · Journal of Clinical Oncology · 2003
DOI 10.1200/jco.2003.07.057
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →